{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:33:02Z","timestamp":1787621582758,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Clinical Research Support Fund of Chinese PLA General Hospital","award":["2018FC-WJFWZX-2-16"],"award-info":[{"award-number":["2018FC-WJFWZX-2-16"]}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"crossref","award":["2019-I2M-5-061"],"award-info":[{"award-number":["2019-I2M-5-061"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer is the fourth most common cancer in women. Early detection and diagnosis play an important role in secondary prevention of cervical cancer. This study aims to provide more information to develop an effective strategy for the prevention and control of cervical cancer in northern China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective single-centre descriptive cross-sectional study was conducted in Chinese PLA General Hospital located in Beijing, covering the period from January 2009 to June 2019. The patients who underwent a polymerase chain reaction (PCR)-based HPV genotyping test and cervical pathological diagnosis were included. Furthermore, we limited the interval between the two examination within 180\u2009days for the purpose of making sure their correlation to analyse their relationship. Moreover, the relationship between different cervical lesions and age as well as single\/multiple HPV infection was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3134 patients were eligible in this study after HPV genotyping test and pathological diagnosis. Most of the patients (95%) were from northern China. Among the patients, 1745(55.68%) had high-grade squamous intraepithelial neoplasia (HSIL), 1354 (43.20%) had low-grade squamous intraepithelial neoplasia (LSIL) and 35 (1.12%) were Normal. The mean age was 42.06\u2009\u00b1\u200910.82(range, 17\u201379\u2009years). The women aged 35\u201349\u2009years accounted for the highest incidence rate. The top five most commonly identified HPV genotypes in each lesion class were as follows: HPV16, 58, 52, 31 and 51 in the class of HSIL; HPV16, 52, 58, 56 and 51 in the class of LSIL; HPV16, 31, 6,11, 52 and 58 in the class of normal. The frequencies of HPV single genotype infection and multiple genotypes infection were 55.26 and 34.18%, respectively. There was no difference in the attributable proportions of multiple genotypes infection amongst HSIL, LSIL and Normal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Northern China, HPV16 was the most dominant genotype in the patients with pathological examination. The peak age of the onset of HSIL was between 35 and 49\u2009years of age. Infection with multiple HPV genotypes did not increase the risk of HSIL. Type-specific HPV prevalence and attribution proportion to cervical precancerous lesions should be taken into consideration in the development of vaccines and strategy for screening in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01383-1","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T09:04:00Z","timestamp":1594631040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in Beijing, China: analysis of results from China\u2019s top 3 hospital, 2009\u20132019"],"prefix":"10.1186","volume":"17","author":[{"given":"Yidi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-2092","authenticated-orcid":false,"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"6","key":"1383_CR1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1383_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21147\/j.issn.1000-9604.2019.02.04","volume":"31","author":"National Health Commission Of The People\u2019s Republic Of China","year":"2019","unstructured":"National Health Commission Of The People\u2019s Republic Of China. Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version). Chin J Cancer Res. 2019;31(2):295\u2013305.","journal-title":"Chin J Cancer Res"},{"key":"1383_CR3","unstructured":"World Health Organization. International Agency for Research on Cancer. Cancer today. [Available from: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/160-china-fact-sheets.pdf."},{"issue":"3","key":"1383_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ijc.26042","volume":"130","author":"JF Shi","year":"2012","unstructured":"Shi JF, Canfell K, Lew JB, Qiao YL. The burden of cervical cancer in China: synthesis of the evidence. Int J Cancer. 2012;130(3):641\u201352.","journal-title":"Int J Cancer"},{"key":"1383_CR5","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","volume":"32","author":"JG Baseman","year":"2005","unstructured":"Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32:S16\u201324.","journal-title":"J Clin Virol"},{"key":"1383_CR6","volume-title":"IAR monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents, vol 100B","author":"International Agency for Research on Cancer","year":"2012","unstructured":"International Agency for Research on Cancer. IAR monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part B: biological agents, vol 100B. Lyon: IARC; 2012. Available from: http:\/\/monographs.iarc.fr\/ENG\/Monographs\/vol100B\/index.php."},{"key":"1383_CR7","first-page":"ED000126","volume":"6","author":"J Morrison","year":"2018","unstructured":"Morrison J, Lasserson T. HPV vaccination: balancing facts. Cochrane Database Syst Rev. 2018;6:ED000126.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1383_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.18553\/jmcp.2010.16.3.217","volume":"16","author":"EP Armstrong","year":"2010","unstructured":"Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16(3):217\u201330.","journal-title":"J Manag Care Pharm"},{"key":"1383_CR9","doi-asserted-by":"publisher","first-page":"c3493","DOI":"10.1136\/bmj.c5128","volume":"341","author":"J Dillner","year":"2010","unstructured":"Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.","journal-title":"BMJ"},{"issue":"8","key":"1383_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1586\/14760584.2015.1051470","volume":"14","author":"J Cuzick","year":"2015","unstructured":"Cuzick J. Gardasil 9 joins the fight against cervix cancer. Expert Rev Vaccines. 2015;14(8):1047\u20139.","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"1383_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"19","key":"1383_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/jnci\/djq326","volume":"102","author":"NT Brewer","year":"2010","unstructured":"Brewer NT, Reiter PL. Re: impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(19):1517 author reply \u22128.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1383_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","volume":"7","author":"S de Sanjose","year":"2007","unstructured":"de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1383_CR14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1046\/j.1525-1438.1999.99020.x","volume":"9","author":"EJ Krul","year":"1999","unstructured":"Krul EJ, Van De Vijver MJ, Schuuring E, Van Kanten RW, Peters AA, Fleuren GJ. Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. Int J Gynecol Cancer. 1999;9(3):206\u201311.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"1383_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","volume":"14","author":"GM Clifford","year":"2005","unstructured":"Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev. 2005;14(5):1157\u201364.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"1383_CR16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.7150\/jca.14971","volume":"7","author":"Z Zeng","year":"2016","unstructured":"Zeng Z, Yang H, Li Z, He X, Griffith CC, Chen X, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51,345 HPV genotyping results from China\u2019s largest CAP certified laboratory. J Cancer. 2016;7(9):1037\u201343.","journal-title":"J Cancer"},{"issue":"2","key":"1383_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5468\/OGS.2013.56.2.110","volume":"56","author":"MJ Kim","year":"2013","unstructured":"Kim MJ, Kim JJ, Kim S. Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: data from the health check-ups of 7,014 Korean women. Obstet Gynecol Sci. 2013;56(2):110\u201320.","journal-title":"Obstet Gynecol Sci"},{"key":"1383_CR18","unstructured":"The rank of Chinese hospital [Available from: http:\/\/jhmhp.amegroups.com\/article\/view\/4014\/4803]."},{"issue":"1","key":"1383_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12885-018-4330-9","volume":"18","author":"H Wang","year":"2018","unstructured":"Wang H, Cheng X, Ye J, Xu X, Hong Y, Sui L, et al. Distribution of human papilloma virus genotype prevalence in invasive cervical carcinomas and precancerous lesions in the Yangtze River Delta area, China. BMC Cancer. 2018;18(1):487.","journal-title":"BMC Cancer"},{"issue":"4","key":"1383_CR20","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.3802\/jgo.2017.28.e30","volume":"28","author":"XL Zhao","year":"2017","unstructured":"Zhao XL, Hu SY, Zhang Q, Dong L, Feng RM, Han R, et al. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population. J Gynecol Oncol. 2017;28(4):e30.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"1383_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.15430\/JCP.2016.21.2.104","volume":"21","author":"KA So","year":"2016","unstructured":"So KA, Hong JH, Lee JK. Human papillomavirus prevalence and type distribution among 968 women in South Korea. J Cancer Prev. 2016;21(2):104\u20139.","journal-title":"J Cancer Prev"},{"issue":"1","key":"1383_CR22","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1186\/s12885-018-5083-1","volume":"18","author":"S Husaiyin","year":"2018","unstructured":"Husaiyin S, Han L, Wang L, Ma C, Ainiwaer Z, Rouzi N, et al. Factors associated with high-risk HPV infection and cervical cancer screening methods among rural Uyghur women aged\u2009>\u200930\u2009years in Xinjiang. BMC Cancer. 2018;18(1):1162.","journal-title":"BMC Cancer"},{"issue":"11","key":"1383_CR23","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/sj.bjc.6603450","volume":"95","author":"LK Li","year":"2006","unstructured":"Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, et al. Human papillomavirus infection in Shenyang City, People\u2019s Republic of China: a population-based study. Br J Cancer. 2006;95(11):1593\u20137.","journal-title":"Br J Cancer"},{"issue":"6","key":"1383_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ijc.22726","volume":"121","author":"RF Wu","year":"2007","unstructured":"Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, et al. Human papillomavirus infection in women in Shenzhen City, People\u2019s Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer. 2007;121(6):1306\u201311.","journal-title":"Int J Cancer"},{"issue":"1","key":"1383_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12879-017-2439-0","volume":"17","author":"G Krashias","year":"2017","unstructured":"Krashias G, Koptides D, Christodoulou C. HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. BMC Infect Dis. 2017;17(1):346.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1383_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10552-013-0320-z","volume":"25","author":"SK Kjaer","year":"2014","unstructured":"Kjaer SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS\/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control. 2014;25(2):179\u201389.","journal-title":"Cancer Causes Control"},{"issue":"4","key":"1383_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.21147\/j.issn.1000-9604.2019.04.10","volume":"31","author":"S Zhao","year":"2019","unstructured":"Zhao S, Zhao X, Hu S, Lu J, Duan X, Zhang X, et al. Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China. Chin J Cancer Res. 2019;31(4):663\u201372.","journal-title":"Chin J Cancer Res"},{"issue":"9","key":"1383_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/sj.bjc.6605351","volume":"101","author":"R Zhao","year":"2009","unstructured":"Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, et al. Human papillomavirus infection in Beijing, People\u2019s Republic of China: a population-based study. Br J Cancer. 2009;101(9):1635\u201340.","journal-title":"Br J Cancer"},{"issue":"11","key":"1383_CR29","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1002\/ijc.28896","volume":"135","author":"FH Zhao","year":"2014","unstructured":"Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer. 2014;135(11):2604\u201311.","journal-title":"Int J Cancer"},{"issue":"2","key":"1383_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178\u201382.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1383_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.20244","volume":"111","author":"N Munoz","year":"2004","unstructured":"Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111(2):278\u201385.","journal-title":"Int J Cancer"},{"issue":"1","key":"1383_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","volume":"88","author":"GM Clifford","year":"2003","unstructured":"Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63\u201373.","journal-title":"Br J Cancer"},{"issue":"9","key":"1383_CR33","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s10552-009-9422-z","volume":"20","author":"W Chen","year":"2009","unstructured":"Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control. 2009;20(9):1705\u201313.","journal-title":"Cancer Causes Control"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01383-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T20:09:45Z","timestamp":1626120585000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01383-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01383-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-19102\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the ethics committees of the Chinese PLA General Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}